Study results showed a modest (12%) advantage for the care management group in control of blood sugar levels, as measured by the proportion of patients whose HbA1c was under 7%. Among the obese patients, the care management group had a 16 percentage point edge (26% vs. 10%) over the usual care group in the proportion of those who lost 5% of their body weight.
Value-based care can’t be done one slice at a time, new value-based models will take aim at variations in care, the patient may gain a stronger voice, the tail could wag the dog, and value-based care will create haves and have-nots. Some predictability from the federal government would be welcome.
They are all physicians. They all want to take care of people. But the chief medical officers at health plans and provider organizations often see the world through different lenses. Here, chief medical officers from both sides of the divide share their views.
Elisabeth Rosenthal has a unique perspective on what ails the American health care system. She is a physician turned journalist who has some firsthand knowledge about what takes place in American hospitals and doctor’s offices, although her Wikipedia entry makes a point of describing her as a “non-practicing physician.”
Shards of a bipartisan effort to stabilize the individual health insurance markets emerged. They focused mostly on resurrecting the ACA cost-reduction payments and giving states flexibility to come up with their own ideas, like reinsurance, for shoring up the troubled individual market.
A MedPage Today blog post suggests that they do. Industry veterans say they’re unaware of bonuses for denials but agree prior auth processes should be more transparent.
Annual family premiums for employer-sponsored health insurance rose an average of 3% in 2017, right in keeping with six years of relatively modest increases. Just over half (53%) of 2,137 companies offered health benefits to at least some of the workers in 2017, according to the Kaiser Family Foundation/Health Research & Trust Employer Health Benefits Survey.
Hemlibra demonstrates how far antibody science has progressed. Genentech’s drug, approved late last year, connects two clotting factors to prevent the devastating bleeds in hemophilia patients with inhibitors. The high price may be offset by avoided costs in patients with factor VIII inhibitors.
Santa Barbara County officials—following the example of large employers such as Boeing and Lowe’s—decided to do a little shopping, and are offering employees incentives to receive care at less expensive, out-of-town hospitals. The savings have been impressive.